This Title All WIREs
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 9.182

Nanotechnology‐based approaches for treating lysosomal storage disorders, a focus on Fabry disease

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Abstract Lysosomal storage disorders (LSDs) are a group of rare diseases in which the defect of a lysosomal protein results in a pathogenic accumulation of nonmetabolized products within the cells. The main treatment for LSDs is enzyme replacement therapy (ERT), consisting in the exogenous administration a recombinant protein to replace the defective one. Although several diseases such as Gaucher, Fabry, and Pompe are treated following this approach, ERT is limited to LSDs without severe neuronal affectation because recombinant enzymes do not cross the blood–brain barrier. Moreover, ERT shows additional drawbacks, including enzyme low half‐life, poor bioavailability, and immunogenic responses. In this scenario, nanotechnology‐based drug delivery systems (DDS) have been proposed as solution to overcome these limitations and improve the efficacy of ERT. The present review summarizes distinct approaches followed by our group and collaborators on the use of DDS for restoring lysosomal enzymes in disease‐affected cells. During the last decade, we have been exploring different synthetic nanoparticles, from electrolytic complexes, to liposomes and aggresomes, for the delivery of α‐galactosidase A (GLA) enzyme. Studies were mainly conducted on Fabry disease models, but results can be also extrapolated to other LSDs, as well as to other diseases treated with alternative therapeutic proteins. The advantages and disadvantages of different DDS, the difficulties from working with very labile and highly glycosylated enzymes and the relevance of using appropriate targeting moieties is thoroughly discussed. Finally, the use of natural DDS, namely extracellular vesicles (EVs) is also introduced. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies
Summary of the enzymatic assays and models used to monitor the efficacy of α‐galactosidase A (GLA) containing drug delivery systems (DDS). (a) Activity of GLA enzyme. In normal (wild type, WT) animals, GLA enzyme cleaves the terminal galactose in Gb3 rendering lactosyceramide (LacCer). In animals without the GLA gene (knock out, KO) and also in Fabry patients, the deficiency of GLA activity leads to the accumulation of Gb3 and other glycosphingolipids, such as lyso‐globotriaosylceramide (lyso‐Gb3). (b) Classic Fabry mouse model by Kulkarni and cols (Ohshima et al., 1997). KO animals show complete absence of GLA enzymatic activity. Effectiveness of GLA nanoparticles in these mice can be followed by measuring Gb3 levels, among other techniques. (c) Enzymatic activity assays of GLA using 4‐methylumbelliferylα‐D‐galactopyranoside (4‐MUG). This assay is used to measure the enzymatic activity in crude samples containing GLA, as well as for following in vivo tissue biodistribution and pharmacokinetics of tested compounds (Abasolo et al., 2019, 2020). (d) Efficacy of GLA systems in cellular models, using mouse aortic endothelial cells (MAEC) (Abasolo et al., 2019, 2020)
[ Normal View | Magnified View ]

Browse by Topic

Therapeutic Approaches and Drug Discovery > Emerging Technologies
Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease
Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts